Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12113265 | 0.84 | GRIA1 (0.49) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113227 | 0.84 | GRIA1 (0.51) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113266 | 0.82 | GRIA1 (0.45) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113263 | 0.81 | GRIA1 (0.50) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113297 | 0.78 | GRIA1 (0.49) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12500772 | 0.74 | LMNA (0.56) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113279 | 0.74 | GRIA1 (0.47) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113245 | 0.74 | GRIA1 (0.59) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12113249 | 0.74 | GRIA1 (0.49) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL14197434 | 0.73 | LMNA (0.51) | GRIA1GRIA2GRIA4GRIK5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993278-B2 | Conjugates for cancer therapy and diagnosis | BIOSIGHT LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| US-8993278-B2 | Conjugates for cancer therapy and diagnosis | BIOSIGHT LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| US-20110275590-A1 | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS | BioSight Ltd., | 2011-11-10 | — | — | US | disclosed |
| US-20110275590-A1 | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS | BioSight Ltd., | 2011-11-10 | — | — | US | disclosed |
| US-7989188-B2 | Conjugates for cancer therapy and diagnosis | BIOSIGHT LTD. (IL) | 2011-08-02 | — | — | US | disclosed |
| US-7989188-B2 | Conjugates for cancer therapy and diagnosis | BIOSIGHT LTD. (IL) | 2011-08-02 | — | — | US | disclosed |
| US-20070072800-A1 | Conjugates for cancer therapy and diagnosis | BIOSIGHT LTD. (IL) | 2007-03-29 | — | — | US | disclosed |
| US-20070072800-A1 | Conjugates for cancer therapy and diagnosis | BIOSIGHT LTD. (IL) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275590-A1 | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS | ASNS, SLC1A5, QPCT | GRIA1 641/4885GRIA2 802/4885GRIA4 949/4885 |
| US-20070072800-A1 | Conjugates for cancer therapy and diagnosis | ASNS, SLC1A5, QPCT | GRIA1 641/4885GRIA2 802/4885GRIA4 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.